US Food and Drug Administration (USFDA) has completed inspection at Granules India’s facility in Gagillapur located in Hyderabad, Telangana, India on February 14, 2020 with two observations. The company will respond to these observations within the stipulated time.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).